stockrow
Friday 6 November 2026
Export CTKB’s income statement to Excel — free account
Cytek Biosciences, Inc.
CTKB Healthcare Medical Devices
Cytek Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $201.5 million, up 0.52% from fiscal 2024.
- Revenue
- +1.79%
- EPS
- −17.0%
- Free cash flow
- −30.3%
- Total debt
- −84.9%
Quarter to September 2026, against a year earlier
5.82
0.42
+7.78%
Follow CTKB
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
3.74 | 2.77 | 2.75 | 3.20 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(174.55) | 419.54 | (205.57) | (836.73) | |
P/B ratio |
2.42 | 1.78 | 1.72 | 1.89 | |
Price to Tangible BV |
2.67 | 1.97 | 1.91 | 2.09 | |
EV/Sales |
2.51 | 1.51 | 1.47 | 1.91 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(79.01) | (51.63) | (41.20) | (81.97) | |
EV/FCF |
(39.03) | (26.05) | (23.83) | (44.54) | |
Quick Ratio |
3.71 | 3.70 | 3.88 | 4.16 | |
Current Ratio |
4.46 | 4.48 | 4.69 | 5.04 | |
Net Debt/EBITDA |
48.22 | 31.11 | 16.73 | 102.35 | |
Debt/Assets |
0.02% | 0.06% | 0.09% | 0.11% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.44 | 0.44 | 0.44 | 0.42 | |
Operating CF/Net income |
0.73 | (0.11) | 0.15 | 0.02 | |
Capex/Depreciation |
(0.48) | (0.75) | (0.78) | (0.28) | |
Interest Coverage |
(32.40) | (40.57) | (70.47) | 7.71 | |
Research and Development Expense of Revenue |
17.58% | 20.23% | 21.76% | 14.42% | |
Selling, General and Administrative Expense of Revenue |
56.88% | 62.32% | 68.23% | 47.50% | |
Intangible Assets out of Total Assets |
0.07 | 0.07 | 0.07 | 0.07 | |
Share Based Compensation of Revenue |
9.12% | 11.09% | 11.01% | 8.89% | |
Graham Net Nets |
0.33 | 0.44 | 0.46 | 0.42 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(10.52%) | (14.00%) | (13.04%) | (10.10%) | |
Free Cash Flow Yield |
(1.72%) | (2.09%) | (2.24%) | (1.34%) | |
Revenue per Share |
0.41 | 0.37 | 0.34 | 0.49 | |
Operating CF per Share |
(0.03) | 0.01 | (0.02) | (0.01) | |
Capex per Share |
(0.01) | (0.02) | (0.02) | (0.01) | |
Free Cash Flow per Share |
(0.05) | (0.01) | (0.04) | (0.01) | |
Cash per Share |
1.97 | 2.02 | 2.04 | 2.05 | |
Shareholders Equity per Share |
2.47 | 2.49 | 2.55 | 2.68 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.47 | 2.49 | 2.55 | 2.68 | |
Free Cash Flow |
(5.93) | (0.87) | (4.93) | (1.61) | |
Working Capital |
293.98 | 293.60 | 298.37 | 314.19 | |
Capital Expenditures |
(1.48) | (2.24) | (2.19) | (0.84) | |
Net Current Asset Value |
254.14 | 252.95 | 257.83 | 272.19 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.03 | 0.05 | 0.05 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
57.91 | 52.97 | 53.47 | 61.55 | |
Average Payables |
6.26 | 7.63 | 6.49 | 5.97 | |
Average Inventory |
52.01 | 50.87 | 47.57 | 46.16 | |
Average Assets |
470.53 | 470.13 | 465.85 | 480.52 | |
Average Common Equity |
349.96 | 349.76 | 353.63 | 368.74 |
Columns are period end dates · fundamentals updated 6 Nov 2026